Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with a poor prognosis and high mortality. More than two-thirds of HNSCC patients still have no effective control of clinical progression, and the five-year survival rate is < 50%. Moreover, patients wi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00532/full |
| _version_ | 1818559732570390528 |
|---|---|
| author | Weimin Lin Miao Chen Le Hong Hang Zhao Qianming Chen |
| author_facet | Weimin Lin Miao Chen Le Hong Hang Zhao Qianming Chen |
| author_sort | Weimin Lin |
| collection | DOAJ |
| description | Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with a poor prognosis and high mortality. More than two-thirds of HNSCC patients still have no effective control of clinical progression, and the five-year survival rate is < 50%. Moreover, patients with platinum-refractory HNSCC have a median survival of < 6 months. The significant toxicity and low survival rates of current treatment strategies highlight the necessity for new treatment modalities. Recently, a large number of studies have demonstrated that programmed cell death protein-1 (PD-1) and its ligand, programmed cell death protein ligand-1 (PD-L1) play an essential role in tumor initiation and progression. PD-1/PD-L1 blockade has shown a desired and long-lasting therapeutic effect in the treatment of HNSCC and other malignancies. However, only a small number of patients with HNSCC can benefit from PD-1/PD-L1 blockade monotherapy, while the majority of patients do not respond. To overcome the unsatisfactory therapeutic effect of PD-1/PD-L1 blockade monotherapy, combining other treatment options for HNSCC (including chemotherapy, radiotherapy, targeted therapy, and immunotherapy) in the treatment scheme has become a commonly used strategy. Herein, the potential mechanisms underlying the crosstalk between PD-1/PD-L1 blockade and its combinatorial therapies for HNSCC were reviewed, and it is hoped that the improved understanding of the crosstalk process would provide further ideas for the design of a combinatorial regimen with a higher efficiency and response rate for the treatment of HNSCC and other malignancies. |
| first_indexed | 2024-12-14T00:29:22Z |
| format | Article |
| id | doaj.art-7cc3324320fe4c1480816c3d1c8f3d70 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T00:29:22Z |
| publishDate | 2018-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7cc3324320fe4c1480816c3d1c8f3d702022-12-21T23:24:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2018-11-01810.3389/fonc.2018.00532418326Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCCWeimin LinMiao ChenLe HongHang ZhaoQianming ChenHead and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide with a poor prognosis and high mortality. More than two-thirds of HNSCC patients still have no effective control of clinical progression, and the five-year survival rate is < 50%. Moreover, patients with platinum-refractory HNSCC have a median survival of < 6 months. The significant toxicity and low survival rates of current treatment strategies highlight the necessity for new treatment modalities. Recently, a large number of studies have demonstrated that programmed cell death protein-1 (PD-1) and its ligand, programmed cell death protein ligand-1 (PD-L1) play an essential role in tumor initiation and progression. PD-1/PD-L1 blockade has shown a desired and long-lasting therapeutic effect in the treatment of HNSCC and other malignancies. However, only a small number of patients with HNSCC can benefit from PD-1/PD-L1 blockade monotherapy, while the majority of patients do not respond. To overcome the unsatisfactory therapeutic effect of PD-1/PD-L1 blockade monotherapy, combining other treatment options for HNSCC (including chemotherapy, radiotherapy, targeted therapy, and immunotherapy) in the treatment scheme has become a commonly used strategy. Herein, the potential mechanisms underlying the crosstalk between PD-1/PD-L1 blockade and its combinatorial therapies for HNSCC were reviewed, and it is hoped that the improved understanding of the crosstalk process would provide further ideas for the design of a combinatorial regimen with a higher efficiency and response rate for the treatment of HNSCC and other malignancies.https://www.frontiersin.org/article/10.3389/fonc.2018.00532/fullcancer immunotherapycombined therapyPD-1PD-L1head and neck squamous cell carcinoma |
| spellingShingle | Weimin Lin Miao Chen Le Hong Hang Zhao Qianming Chen Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC Frontiers in Oncology cancer immunotherapy combined therapy PD-1 PD-L1 head and neck squamous cell carcinoma |
| title | Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC |
| title_full | Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC |
| title_fullStr | Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC |
| title_full_unstemmed | Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC |
| title_short | Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC |
| title_sort | crosstalk between pd 1 pd l1 blockade and its combinatorial therapies in tumor immune microenvironment a focus on hnscc |
| topic | cancer immunotherapy combined therapy PD-1 PD-L1 head and neck squamous cell carcinoma |
| url | https://www.frontiersin.org/article/10.3389/fonc.2018.00532/full |
| work_keys_str_mv | AT weiminlin crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc AT miaochen crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc AT lehong crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc AT hangzhao crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc AT qianmingchen crosstalkbetweenpd1pdl1blockadeanditscombinatorialtherapiesintumorimmunemicroenvironmentafocusonhnscc |